Saturday 17 October 2026
Export WAT’s income statement to Excel — free account
Waters Corporation
WAT Healthcare Diagnostics & Research
Waters Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 6.99% from fiscal 2024. In the quarter to June 2026, revenue grew 113.4%, EPS fell 156.3%, free cash flow grew 750.0% and total debt rose 308.2%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
436.95
7.20
−1.62%
Follow WAT
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 112.00 | 134.68 | 167.94 | 174.95 | 154.39 | 244.77 | 265.61 | 231.90 | 279.24 | 275.05 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 162.53 | 201.95 | 220.20 | 255.21 | 252.67 | 428.22 | 372.24 | 350.97 | 397.02 | 423.56 | |||||
| People | |||||||||||||||
| People | Employees | 6,900 | 7,000 | 7,200 | 7,500 | 7,400 | 7,800 | 8,200 | 7,900 | 7,600 | 7,900 | ||||
| Revenue/emp, $m | 0.31 | 0.33 | 0.34 | 0.32 | 0.32 | 0.36 | 0.36 | 0.37 | 0.39 | 0.40 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | 2,167 | 2,309 | 2,420 | 2,407 | 2,365 | 2,786 | 2,972 | 2,956 | 2,958 | 3,165 | ||||
| Gross margin, % | 58.87 | 58.99 | 58.98 | 58.00 | 57.44 | 58.49 | 58.00 | 59.57 | 59.43 | 59.28 | |||||
| EBT | 600 | 641 | 682 | 678 | 611 | 806 | 838 | 736 | 755 | 755 | |||||
| EBT margin, % | 27.69 | 27.76 | 28.19 | 28.18 | 25.83 | 28.94 | 28.19 | 24.90 | 25.52 | 23.85 | |||||
| Net income | 522 | 20 | 594 | 592 | 522 | 693 | 708 | 642 | 638 | 643 | |||||
| Depreciation | 96 | 106 | 108 | 105 | 125 | 132 | 130 | 166 | 192 | 206 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 26.83 | 28.94 | 31.43 | 35.59 | 38.09 | 45.24 | 49.55 | 50.04 | 49.86 | 53.19 | ||||
| Earnings | 6.46 | 0.25 | 7.71 | 8.76 | 8.40 | 11.25 | 11.80 | 10.87 | 10.75 | 10.80 | |||||
| Cash flow | 7.96 | 8.74 | 7.85 | 9.51 | 12.73 | 12.14 | 10.20 | 10.20 | 12.84 | 10.97 | |||||
| Capex | (1.13) | (1.13) | (1.25) | (2.42) | (4.07) | (2.73) | (3.06) | (24.43) | (2.40) | (2.44) | |||||
| Free cash flow | 6.83 | 7.61 | 6.60 | 7.09 | 8.66 | 9.40 | 7.14 | (14.22) | 10.44 | 8.53 | |||||
| Book value | 28.49 | 27.99 | 20.36 | (3.20) | 3.74 | 5.97 | 8.41 | 19.47 | 30.82 | 43.04 | |||||
| Shares, m | 81 | 80 | 77 | 68 | 62 | 62 | 60 | 59 | 59 | 60 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | 21.09 | 815.38 | 24.37 | 26.40 | 29.49 | 33.06 | 29.24 | 30.18 | 34.48 | 35.20 | ||||
| P/S | 5.09 | 6.76 | 6.00 | 6.57 | 6.50 | 8.24 | 6.98 | 6.57 | 7.44 | 7.14 | |||||
| P/B | 4.79 | 6.99 | 9.27 | 0.00 | 66.18 | 62.42 | 41.09 | 16.88 | 12.04 | 8.82 | |||||
| EV/Sales | 4.57 | 6.11 | 5.76 | 7.08 | 6.82 | 8.57 | 7.33 | 7.21 | 7.88 | 7.25 | |||||
| EV/FCF | 18.50 | 23.25 | 27.69 | 35.94 | 30.28 | 41.26 | 50.85 | (25.38) | 37.62 | 45.24 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | 643 | 698 | 604 | 643 | 791 | 747 | 612 | 603 | 762 | 653 | ||||
| Capex | (91) | (90) | (96) | (164) | (253) | (168) | (183) | (1,443) | (142) | (145) | |||||
| Free cash flow | 552 | 607 | 508 | 479 | 538 | 579 | 428 | (840) | 620 | 508 | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 3,115 | 3,664 | 2,214 | 721 | 596 | 948 | 978 | 963 | 879 | 908 | ||||
| Total debt | 1,702 | 1,898 | 1,148 | 1,581 | 1,207 | 1,514 | 1,525 | 2,306 | 1,626 | 947 | |||||
| Net debt | (1,111) | (1,496) | (587) | 1,244 | 763 | 945 | 1,043 | 1,910 | 1,301 | 360 | |||||
| Shareholders’ equity | 2,302 | 2,234 | 1,567 | (216) | 232 | 368 | 504 | 1,150 | 1,829 | 2,561 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | 11.68 | 0.41 | 13.12 | 18.85 | 19.33 | 23.35 | 22.20 | 16.24 | 13.90 | 13.35 | ||||
| ROIC | 32.80 | 56.11 | 47.17 | 43.10 | 40.52 | 39.14 | 35.26 | 16.70 | 16.50 | 17.17 | |||||
| ROE | 23.92 | 0.90 | 31.24 | 87.67 | 6,576.65 | 231.06 | 162.32 | 77.62 | 42.82 | 29.28 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Waters Corporation vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NTRA Natera, Inc. | $58.4B | — (loss-making) | — (loss-making) | +37.71% (above 0%: growing) | n/m | −173.96% (below 0%: shrinking) | 64.46% | (10.07%) | Compare |
| A Agilent Technologies, Inc. | $49.5B | 34.0× | 26.3× | +8.06% (above 0%: growing) | +8.47% (above 0%: growing) | +69.50% (above 0%: growing) | 55.48% | 23.64% | Compare |
| IQV IQVIA Holdings Inc. | $44.6B | 32.8× | 22.3× | +8.74% (above 0%: growing) | −0.65% (below 0%: shrinking) | +23.29% (above 0%: growing) | 32.85% | 11.58% | Compare |
| WAT Waters Corporation | $43.6B | 109× | 44.3× | +113.36% (above 0%: growing) | n/m | +750.00% (above 0%: growing) | 44.62% | (5.23%) | |
| IDXX IDEXX Laboratories, Inc. | $43.1B | 39.1× | 38.3× | +9.66% (above 0%: growing) | +17.21% (above 0%: growing) | +111.44% (above 0%: growing) | 64.04% | 34.98% | Compare |
| ILMN Illumina, Inc. | $40.5B | 48.4× | 34.7× | +9.44% (above 0%: growing) | −8.05% (below 0%: shrinking) | −18.27% (below 0%: shrinking) | 66.44% | 21.14% | Compare |
| MTD Mettler-Toledo International, Inc. | $32.8B | 36.4× | 25.5× | +4.48% (above 0%: growing) | +18.30% (above 0%: growing) | +33.01% (above 0%: growing) | 63.29% | 30.61% | Compare |
| DGX Quest Diagnostics Incorporated | $26.4B | 24.6× | 20.8× | +10.21% (above 0%: growing) | +14.74% (above 0%: growing) | +5.28% (above 0%: growing) | 33.75% | 15.08% | Compare |
| LH Labcorp Holdings Inc. | $26.4B | 26.2× | 19.0× | +5.78% (above 0%: growing) | +28.42% (above 0%: growing) | −42.01% (below 0%: shrinking) | 29.80% | 12.10% | Compare |
| Median of peers | $41.8B | 34.0× | 25.5× | +9.09% | +14.74% | +14.29% | 59.39% | 18.11% |
WAT metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
Waters Corporation (WAT) key facts
- Strength: Waters Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 6.99% from fiscal 2024.
- Waters Corporation (WAT) is a Diagnostics & Research company in the Healthcare sector, listed on the New York Stock Exchange.
- As of October 16, 2026, WAT traded at $436.95, a market capitalization of $43.6 billion.
- Return on equity was 29.3% and debt-to-equity 0.32.
- Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 9.63 (safe zone) for fiscal 2025.